GMAB
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a premium to deterministic value but a discount to sector P/E.
- Low P/E relative to peers
- Price exceeds Graham Number ($18.13)
- Price exceeds Intrinsic Value ($10.78)
Growth is inconsistent; short-term revenue spikes contrast with annual earnings drops.
- Strong Q/Q revenue growth
- Bullish analyst targets
- Negative YoY earnings growth
- High PEG ratio (1.75)
Recent recovery is overshadowed by long-term value erosion.
- Strong 1-year return (+50.2%)
- Negative 3Y and 5Y returns
- Inconsistent earnings beat record
Financial health is stable but not strong.
- Piotroski F-Score 4/9 (Stable)
- Healthy Current/Quick ratios (~2.0)
- Debt/Equity near 1.0
- Lack of Altman Z-Score data
Non-dividend paying growth/biotech stock.
- No dividend yield
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GMAB and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GMAB
Genmab A/S
Primary
|
-15.8% | -27.2% | +50.2% | -11.2% | +1.1% | +2.8% |
|
ZBH
Zimmer Biomet Holdings, Inc.
Peer
|
-38.9% | -27.0% | -18.2% | -7.5% | -8.3% | +4.1% |
|
HOLX
Hologic, Inc.
Peer
|
+1.7% | -6.2% | +23.1% | +12.7% | +0.2% | +0.1% |
|
CNC
Centene Corporation
Peer
|
-46.2% | -47.4% | -43.7% | -4.8% | -23.7% | +3.9% |
|
INCY
Incyte Corporation
Peer
|
+13.4% | +30.2% | +55.4% | +11.0% | -5.9% | +3.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GMAB
Genmab A/S
|
NEUTRAL | $17.46B | 18.36 | 17.5% | 25.9% | $28.28 | |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
NEUTRAL | $18.03B | 25.63 | 5.6% | 8.6% | $90.97 | Compare |
|
HOLX
Hologic, Inc.
|
NEUTRAL | $16.87B | 31.36 | 10.9% | 13.2% | $75.58 | Compare |
|
CNC
Centene Corporation
|
BEARISH | $16.73B | - | -28.7% | -3.8% | $34.02 | Compare |
|
INCY
Incyte Corporation
|
BULLISH | $18.73B | 15.3 | 29.9% | 25.0% | $94.12 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GMAB from our newsroom.